DYN
Dyne Therapeutics, Inc.
$17.37
+0.00
(+0.00%)
Mkt Cap
2.87B
Volume
1,405,056
52W Range
8.06-25
Sector
Healthcare
Beta
1.08
EPS (TTM)
-3.22
P/E Ratio
-5.63
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 506.00M | 1.37B | 842.00M | 1.47B |
| Net Income | (446.21M) | (317.42M) | (235.94M) | (168.10M) | (149.29M) | (58.74M) | (13.54M) | (4.81M) | 76.00M | (1.24B) | 50.00M | (67.00M) |
| EPS | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -1.24 | -0.30 | -0.47 | 0.47 | -9.61 | 0.40 | -0.53 |
| Free Cash Flow | (405.13M) | (294.75M) | (188.89M) | (156.71M) | (123.18M) | (47.67M) | (13.48M) | (4.30M) | 361.00M | 350.00M | N/A | N/A |
| FCF / Share | -3.15 | -3.13 | -3.16 | -3.02 | -2.42 | -1.01 | -0.30 | -0.42 | 2.23 | 2.71 | N/A | N/A |
| Operating CF | (403.21M) | (292.37M) | (188.16M) | (153.65M) | (119.56M) | (46.51M) | (11.83M) | (4.16M) | 585.00M | 676.00M | N/A | N/A |
| Total Assets | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M | 353.33M | 16.44M | 8.27M | 11.77B | 13.05B | N/A | N/A |
| Total Debt | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M | 0 | 0 | 3.38M | 8.43B | 8.98B | N/A | N/A |
| Cash & Equiv | 893.37M | 435.45M | 121.63M | 172.15M | 200.82M | 300.85M | 14.63M | 8.12M | 365.00M | 1.78B | N/A | N/A |
| Book Value | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M | 342.37M | 14.04M | (4.88M) | 1.90B | 2.04B | N/A | N/A |
| Return on Equity | -0.46 | -0.50 | -2.58 | -0.67 | -0.41 | -0.17 | -0.96 | N/A | 0.04 | -0.61 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (120.85M) | (111.95M) | (108.04M) | (110.86M) | (115.36M) | (89.54M) | (97.12M) | (65.10M) | (65.65M) | (66.64M) | (60.21M) | (64.90M) |
| EPS | -0.73 | -0.76 | -0.76 | -0.97 | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 | -1.09 | -0.99 | -1.08 |
| Free Cash Flow | (145.14M) | (112.32M) | (109.96M) | (94.76M) | (106.87M) | (85.41M) | (74.88M) | (55.73M) | (78.73M) | (35.09M) | (50.77M) | (55.89M) |
| FCF / Share | -0.88 | -0.87 | -0.78 | -0.83 | -0.97 | -0.84 | -0.74 | -0.60 | -0.97 | -0.57 | -0.83 | -0.93 |
| Operating CF | (144.92M) | (111.83M) | (90.78M) | (94.70M) | (105.89M) | (84.33M) | (74.63M) | (54.87M) | (78.54M) | (35.01M) | (50.60M) | (55.64M) |
| Total Assets | 1.08B | 1.19B | 867.06M | 728.99M | 721.07M | 691.23M | 768.84M | 825.88M | 522.28M | 165.08M | 205.24M | 251.42M |
| Total Debt | 19.30M | 20.28M | 120.47M | 121.08M | 23.33M | 23.99M | 24.86M | 25.72M | 26.62M | 27.41M | 28.23M | 29.04M |
| Cash & Equiv | 753.10M | 893.37M | 573.61M | 485.04M | 472.25M | 435.45M | 532.16M | 608.20M | 272.04M | 121.63M | 130.28M | 167.61M |
| Book Value | 865.05M | 972.13M | 691.78M | 571.45M | 668.97M | 629.84M | 705.54M | 775.19M | 478.06M | 91.29M | 152.04M | 206.88M |
| Return on Equity | -0.14 | -0.12 | -0.16 | -0.19 | -0.17 | -0.14 | -0.14 | -0.08 | -0.14 | -0.73 | -0.40 | -0.31 |
DYN News
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting